1. Introduction {#sec1-1}
===============

Aggressive periodontitis shows a rapid attachment loss related to compromised host immune reaction and greatly pathogenic microorganisms ([@ref16]). A recent systematic review and meta-analysis indicated that for the management of aggressive periodontitis subjects, adjunctive antibiotics plus mechanical therapy occasioned a considerable supplementary benefit than mechanical treatment alone; a tendency presented that amoxicillin plus metronidazole (AMOX+METRO) is the most effective antimicrobial protocol ([@ref16]). Also, a clinical study documented that systemic moxifloxacin (MOX) leads to better advantages than scaling and root planing (SRP) in subjects with aggressive periodontitis (GAgP) ([@ref2]). Adjunctive AMOX+METRO ([@ref11]; [@ref8]) and MOX ([@ref2]) have showed higher benefits in clinical attachment level (CAL) increase and probing depth (PD) diminution in comparation to SRP alone in aggressive periodontitis.

Nevertheless, it has been reported that clinical results of mechanical therapy could differ not simply among subjects but likewise among different sites of the tooth in the patient ([@ref19]). This concern has been elucidated by various researchers in periodontitis patients treated with SRP, adjunctive antibiotics, surgical therapy and combinations of these therapies ([@ref5]; Tomasi, Koutouzis, & Wennström, 2007; [@ref13]; [@ref12]; [@ref15]). Most of these clinical studies have contemplated chronic periodontitis patients, but almost nothing is known in aggressive periodontitis subjects. Also, a meta-analysis ([@ref11]) indicated that the efficacy of AMOX+MET in aggressive periodontitis subjects is lower after 3 months than the efficacy in chronic periodontitis subjects; nevertheless, the efficacy of AMOX+MET was advanced at six and twelve months in aggressive periodontitis than in chronic periodontitis subjects. Besides, systematic reviews ([@ref10]; [@ref9]) have recommended that the additional advantage estimated from antimicrobial treatment could be better in subjects with aggressive periodontitis. These results could indicate that adjunctive antibiotics have not the same effect in chronic than in aggressive periodontitis patients.

Considering some particularities of aggressive periodontitis, namely, age of beginning, periods of advance, forms of damage and clinical evidence of swelling ([@ref3]), among others, the influence of the fundamentally ordered configuration of periodontal figures in the treatment of aggressive periodontitis must be explored. It is coherent to contemplate that based on these particularities periodontal treatment could diverge not simply between individuals but also among tooth sites in aggressive periodontitis patients.

To our understanding, no investigations have assessed the influence of the hierarchical organization of periodontal information in determining the variability of the clinical outcomes after adjunctive MOX in aggressive periodontitis. Also, adjunctive MOX has been scarcely studied in clinical trials, particularly in aggressive periodontitis. Thus, the aim of this multilevel analysis was to investigate clinical factors that influence variations in clinical attachment increase and probing depth diminution of adjunctive MOX compared to SRP alone at six months post-treatment in GAgP patients.

2. Method {#sec1-2}
=========

Comprehensive descriptions of the clinical trial design containing patients' selection, randomization, allocation, therapy, adherence and clinical evaluation have been previously published ([@ref2]). A concise description is given here.

2.1 Subjects {#sec2-1}
------------

The subjects had at minimum twenty teeth, excepting third molars and teeth designated for removal. The study protocol was permitted by the Ethics Board on the Faculty of Dentistry of the Universidad de Antioquia agreeing to the Declaration of Helsinki. All individuals were informed independently concerning the purposes, possible dangers and advantages of the therapies and signed the informed agreement.

The diagnosis of GAgP was made following the recommendations of the American Academy of Periodontology ([@ref4]).

2.2 Investigational Scheme and Therapy {#sec2-2}
--------------------------------------

Both therapies included mechanical therapy plus adjunctive MOX (400 mg one per day for seven days) or SRP plus placebo (control group) one per day for seven days. An equalized chance block system was accomplished to organize the randomization sequence to evade unequal equilibrium between both therapies. The randomization list was referred to a clinical director no involved in the investigation, which applied the distribution. Consequently, therapy allocations were distributed to numbered obscure packets.

2.3 Clinical Evaluation {#sec2-3}
-----------------------

Patients were examined at baseline and at six months after treatment. At each checking appointment, detectable plaque, bleeding on probing (BOP), PD and CAL were determined at six sites of each tooth (excepting third molars). The PD and CAL lengths were documented to the closest millimeter by a standardized probe (UNC-15, Hu-Friedy, Chicago, IL).

The same blinded, qualified and standardized clinician completed the evaluation at all appointments for selected patients. The examiner dentist did not execute the treatment on the patients. The intra-examiner concordance was calculated before and through the experimental phase. The intra-class concordance for average CAL and PD were 0.91 and 0.92, correspondingly.

2.4 Primary and Secondary Outcome Variables {#sec2-4}
-------------------------------------------

In the present multilevel analysis, a change in CAL regarding baseline and six months (ΔCAL) was measured as the primary outcome characteristic. Secondary result variable contained changes for the average variations of PD. Consequently, a difference in PD concerning baseline and six months (ΔPD) was considered as a dependent variable.

The sample size to guarantee sufficient power was estimated contemplating changes of one mm for CAL and a standard deviation of 1 mm between treatments ([@ref20]). Considering these estimates, it was established that ≥12 patients per protocol would be required to supply 80% power with an α of 0.05. To compensate drop-out proportion, 20 subjects were enlisted per therapy protocol.

2.5 Statistical Analysis {#sec2-5}
------------------------

Changes in quantitative and qualitative parameters were assessed by independent t-test (data were distributed normally) and *X*^2^ test, respectively. Independent t-test was executed to define the changes between treatments concerning differences in clinical parameters (CAL and PD). A repeated-measures ANOVA was performed to identify intra-group changes in clinical factors. These analyses were implemented operating a statistical software (Statistical Package for the Social Sciences, version 18, Chicago, IL). The alpha was established to 5%.

Three levels of variability were demarcated: the subject, the tooth, and the site. Patient factors incorporated age (years), gender, plaque and BOP scores and treatments (Adjunctive MOX versus SRP+placebo). Tooth parameters included one categorical variable: molars/non-molars. Site characteristics considered location (interproximal versus buccal/lingual). Variance models (empty models) were created calculating differences in CAL (ΔCAL) and PD (ΔPD) regarding baseline and six months as dependent variables without incorporating explanatory variables. The empty models were computing considering the complete variation of ΔCAL and ΔPD and to assign it to the subject, tooth, and site levels. A sequence of explicatory factors was formerly analysed (multivariate models) in order to calculate the association between each explicatory variable and the dependent variable. When the explanatory variable was statistically significant, the interaction with MOX was also included in the multivariate model.

Consequently, multilevel linear models for continuous variables were analysed, incorporating examinations for the normality of the residuals at the diverse levels. Multicollinearity examination was executed for each independent variable. Regression coefficients were calculated operating iterative general least squares. Nested models were examined for significant advances in model fitting by relating the diminution in -2 log likelihood (-2LL) with a *X*^2^ allocation. All multilevel analyses were completed executing a statistical package (MLwin 2.02, London, UK). The alpha was established to 5%.

3. Results {#sec1-3}
==========

This experimental study had six months of development. A total of 40 subjects who joined the dental clinics of the Universidad de Antioquia, Medellín, Colombia, were enrolled between February 2012 and August 2013.

Of the 40 patients enrolled, 36 patients had all the information for all examinations while four patients had one absent appointment. Intent-to-treat analyses were executed in the 4 patients with absent information; consequently the final examination was passed forward, offering a total of 40 patients with full information that were involved in the analyses. Flow chart of the trial design was explained earlier ([@ref2]).

Patients enlisted in the clinical trial described complete adherence to the recommended sequence of MOX and placebo and nobody informed unfavorable episode related with the treatment.

The baseline features of the patients have been formerly presented ([@ref2]); there were no observed dissimilarities between protocols for socio-demographic characteristics.

The factors related with the three levels that were investigated are specified in [Table 1](#T1){ref-type="table"}.

###### 

Age, gender and baseline parameters associated with patient, tooth and site levels

  --------------------------------------------------------------------------------
  Parameter                                                        Value
  ---------------------------------------------------------------- ---------------
  Patients                                                         *N*= 40

  Age (mean±SD)                                                    27.4±1

  Gender (male/female)                                             17/23

  Treatment (Moxifloxacin/mechanical therapy)                      20/20

  Plaque score (mean±SD)                                           44±13

  Bleeding on Probing score (mean±SD)                              46±13

  Tooth                                                            *N*=1079

  Site                                                             *N*=6474

  Probing Depth (mean±SD)                                          4.3±0.4

  Clinical Attachment Level (mean±SD) Position (db/b/mb/dl/l/ml)   4.9±0.5\
                                                                   1079 each one
  --------------------------------------------------------------------------------

SD: standard deviation; db: distobuccal; b: buccal; mb: mesiobuccal; dl: distolingual; l: lingual; ml: mesiolingual.

The data involved 6474 tooth sites at 1079 teeth in 40 patients. Variations in CAL and PD in the two groups through the trial phase are observed in [Table 2](#T2){ref-type="table"}. In both treatments protocols a significant diminution of PD and CAL increase was observed (p\<0.0001), and this change was preserved after six months. The changes between therapies were significant after treatment, favouring the MOX group (p\<0.001).

###### 

Changes in the clinical parameters in the two protocols during the trial phase

  Parameter                             Moxifloxacin                                                                            Control group                              
  ------------------------------------- ------------------------------------------ -------------------------------------------- ------------------------------------------ --------------------------------------------
                                        Baseline                                   6 months                                     Baseline                                   6 months
  Clinical Atthacment Level (mean±SD)   4.92±0.5[\*](#t2f1){ref-type="table-fn"}   3.14±0.6[\*\*](#t2f2){ref-type="table-fn"}   4.93±0.4[\*](#t2f1){ref-type="table-fn"}   3.77±0.4[\*\*](#t2f2){ref-type="table-fn"}
  Probing Depth (mean±SD)               4.27±0.4[\*](#t2f1){ref-type="table-fn"}   3.08±0.6[\*\*](#t2f2){ref-type="table-fn"}   4.34±0.5[\*](#t2f1){ref-type="table-fn"}   3.5±0.4[\*\*](#t2f2){ref-type="table-fn"}

SD: standard deviation;

Changes were detected among the two time evaluations (repeated-measures ANOVA p\<0.001);

Changes were perceived between the treatments (*t* -test *p*\<0.001).

Results from the empty multilevel models with ΔCAL and ΔPD as the dependent variables are presented in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

Hierarchical regression analysis assessing the influence of subject, tooth and site characteristics in the variability of clinical attachment level (CAL) gain

  Intercept           ΔCAL Baseline-6months                              
  ------------------- -------------------------------------------------- ---------------------------------------------------
                      2.974±0.095                                        3.743±0.225
  Patient (Level 3)   0.317±0.081 (16) [‡](#t3f1){ref-type="table-fn"}   0.237±0.059 (-25%)[•](#t3f2){ref-type="table-fn"}
  Tooth (Level 2)     1.183±0.054 (60) [‡](#t3f1){ref-type="table-fn"}   0.732±0.034 (-38%)[•](#t3f2){ref-type="table-fn"}
  Site (Level 1)      0.461±0.009 (24) [‡](#t3f1){ref-type="table-fn"}   0.308±0.006 (-33%)[•](#t3f2){ref-type="table-fn"}
  Total variance      1.961                                              1.277
  -2 LL               17083.055                                          12305.077[\*](#t3f1){ref-type="table-fn"}

Proportion of variability in ΔCAL provided by the multilevel analysis at the subject, tooth, and site levels.

Change in the proportion of variability in ΔCAL at the subject, tooth, and site levels when explicatory factors were incorporated in the analysis.

Variation in -2 LL was significant (*P*\<0.001).

###### 

Hierarchical regression analysis assessing the influence of subject, tooth and site characteristics in the variability of probing depth (PD) reduction

  Intercept           ΔPDBaseline-6months                               
  ------------------- ------------------------------------------------- ---------------------------------------------------
                      2.816±0.084                                       3.622±0.264
  Patient (Level 3)   0.246±0.063 (17)[‡](#t4f1){ref-type="table-fn"}   0.203±0.051 (-17%)[†](#t4f2){ref-type="table-fn"}
  Tooth (Level 2)     0.885±0.040 (61)[‡](#t4f1){ref-type="table-fn"}   0.711±0.033 (-20%)[†](#t4f2){ref-type="table-fn"}
  Site (Level 1)      0.325±0.006 (22)[‡](#t4f1){ref-type="table-fn"}   0.304±0.006 (-9%)[†](#t4f2){ref-type="table-fn"}
  Total variance      1.456                                             1.218
  -2 LL               14790.139                                         10193.559[\*](#t4f3){ref-type="table-fn"}

Proportion of variability in ΔPD provided by the multilevel analysis at the subject, tooth, and site levels.

Change in the proportion of variability in ΔCAL at the subject, tooth, and site levels when explicatory factors were incorporated in the analysis

Variation in -2 LL was significant (*P*\<0.001)

The empty model for ΔCAL provided a total unexplained variance of 1.96, the majority attributed to variation between teeth (60%), followed by between sites (24%) and between subjects (16%). The addition of the explanatory variables occasioned a 35% diminution of the entirely inexplicable variability: 25%, 38% and 33% at the subject, tooth and site levels, respectively. Appreciably superior fit was reached introducing the clinical explicatory variables at the three levels (P\<0.05) ([Table 3](#T3){ref-type="table"}).

The empty model for ΔPD presented a total unexplained variance of 1.46, the majority accredited to variation between teeth (61%), followed by between sites (22%) and between subjects (17%). The insertion of the explanatory variables conducted to a 17% diminution of the absolutely inexplicable variability: 17%, 20% and 9% at the subject, tooth and site levels, respectively. Meaningfully improved fit was accomplished including the clinical explanatory variables at the three levels (P\<0.05) ([Table 4](#T4){ref-type="table"}).

[Table 5](#T5){ref-type="table"} depicts the multilevel multivariate model studying the explicatory variables analysing ΔCAL as the outcome variable. At the subject level, adjunctive MOX showed a significantly more positive response in terms of CAL gain (P=0.02). At the tooth level, the analysis demonstrated that non-molars presented the best significant gains in CAL than molars (P\<0.0001). Furthermore, the interaction non-molar x MOX was significantly associated with CAL gain at six months (P\<0.0001). Finally, at the site level, interproximal locations were the zones where CAL gains were superior to at the buccal/lingual sites (P=0.02). Also, the interaction interproximal sites x MOX was significantly associated with CAL gain at six months (P\<0.0001).

###### 

Hierarchical regression analysis assessing the influence of subject, tooth and site factors, describing the variance in clinical attachment level (CAL) gains

  Parameters                          ΔCAL Baseline-6months (β±SE)   P value    
  ----------------------------------- ------------------------------ ---------- --
  Subject Level                                                                 
   Adjunctive MOX/SRP+placebo         0.620±0.309                    0.02       
  Tooth Level                                                                   
   Tooth position (non-molar/molar)   0.845±0.069                    \<0.0001   
   Non-molar x MOX                    -0.311±0053                    \<0.0001   
  Site Level                                                                    
   (db-mb-dl-ml/b-l)                  0.055±0.028                    0.02       
   (db-mb-dl-ml) x MOX                -0.295±0.026                   \<0.0001   

db: distobuccal; b: buccal; mb: mesiobuccal; dl:distolingual; l: lingual; ml: mesiolingual.

A similar tendency shows the multilevel multivariate model investigating the explanatory variables influencing ΔPD as the dependent variable ([Table 6](#T6){ref-type="table"}). At the patient level, adjunctive MOX showed a significantly more advantageous response in terms of PD reduction (P=0.04). At the tooth level, the analysis demonstrated that non-molars presented the best reductions in PD than molars (P\<0.0001). Moreover, the interaction non-molar x MOX was significantly associated with PD reduction at six months (P\<0.0001). Also, at the site level, interproximal positions were the parts where PD reductions were superior to at the buccal/lingual sites (P=0.01). Besides, the interaction interproximal sites x MOX was significantly associated with PD reduction at six months (P=0.02).

###### 

Hierarchical regression analysis assessing the influence of subject, tooth and site factors, describing the variance in probing depth (PD) reduction

  Parameters                          ΔCAL Baseline-6months (β±SE)   P value    
  ----------------------------------- ------------------------------ ---------- --
  Subject Level                                                                 
   Adjunctive MOX/SRP+placebo         0.781±0.454                    0.04       
  Tooth Level                                                                   
   Tooth position (non-molar/molar)   0.817±0.058                    \<0.0001   
   Non-molar x MOX                    -0.914±0.185                   \<0.0001   
  Site Level                                                                    
   (db-mb-dl-ml/b-l)                  0.045±0.020                    0.01       
   (db-mb-dl-ml) x MOX                -0.130±0.064                   0.02       

db: distobuccal; b: buccal; mb: mesiobuccal; dl:distolingual; l: lingual; ml: mesiolingual.

4. Discussion {#sec1-4}
=============

The application of surrogate parameters such as PD and CAL to estimate the clinical success of several therapies is a usual method ([@ref6]). In this report, variations in CAL and PD between baseline and 6 months after adjunctive MOX to one-stage full-mouth SRP compared to SRP alone were evaluated using a multilevel approach. Consequently, the main cause of variability in CAL gain and PD reduction following adjunctive MOX was referable to the tooth level, followed by the site and the subject levels. Comparable effects were documented in a previous multilevel analysis relating nonsurgical and surgical therapy in subjects with aggressive and chronic periodontitis ([@ref12]). Also, merely elements at the tooth position level were recognized by a multilevel model as significant for the management result of adjunctive doxycycline for the re-instrumentation of pathologic sites in subjects with chronic periodontitis ([@ref18]).

In the present research, the final model for ΔCAL, including all of the significant factors conducted to a 35% diminution of the entirely inexplicable variability. Besides, the final model for ΔPD conducted to a 17% decrease of the total inexplicable variation being higher at the tooth level. These conclusions focus the significance of considering factors related with the tooth level in order to elect periodontal therapy properly. In line, the observations reported by [@ref17] recommend focusing on factors at the tooth level in order to explore for supplementary elements that may impact the projection of the result of pathologic pockets in patients with chronic periodontitis. A similar recommendation could apply in aggressive periodontitis.

In the current study, the multilevel models associated CAL gain and PD reduction with adjunctive MOX (at the patient level); non-molar and the interaction non-molar x MOX (at the tooth level); and interproximal sites and the interaction interproximal sites x MOX (at the site level). The significant interactions between MOX with non-molar and interproximal sites show that MOX could be a crucial factor for PD reduction and CAL gain in GAgP.

To the best knowledge of the authors, this is the initial experimental study that evaluates the influence of different factors at the subject, tooth and site levels in the adjunctive MOX treatment of patients diagnosed with GAgP. Previous investigations have studied subjects with chronic and aggressive periodontitis managed with various forms of therapies ([@ref5]; [@ref17]; [@ref13]; [@ref12]; [@ref15]). Curiously, the efficacy of systemic MOX in chronic periodontitis using a multilevel approach has not been evaluated previously. However, the efficacy of adjunctive MOX regarding PD diminution and CAL increase has been also perceived in chronic periodontitis patients ([@ref7]). Also, using multilevel models, [@ref13] showed that adjunctive AMOX+MET presented more clinical advantages than others therapies. Overall, our results corroborate the published information presented earlier showing that treatment results in dissimilar positions and teeth in the identical subject are not independent ([@ref17]; [@ref13]; [@ref12]).

In this report, worst results were detected in molars, which is in agreement with conclusions informed by others researchers who applied hierarchical approaches in the evaluation of the therapy effect ([@ref5]; [@ref17]; [@ref13]); this observation may be related to difficult accessibility for subgingival SRP in molars ([@ref17]). [@ref12] in a multilevel analysis reported more pronounced PD diminution and CAL increase in single-rooted teeth. In line, [@ref15] indicated that in non-molar that were treated with AMOX+MET fewer sites remained with PD\>4mm and BOP. Also here, the interaction non-molar and MOX was associated with greater PD reduction and CAL gain.

This multilevel analysis showed that at the site level more diminutions in PD were detected for interdental positions than in buccal/lingual sites. This is in conformity with preceding information ([@ref5]; [@ref17]) and coherent with the predominant situation of profounder pockets in the interdental spaces ([@ref5]). In this report, the interaction interproximal sites and MOX was associated with higher PD diminution and CAL increase. In accordance, a recent meta-analysis indicated that systemic antibiotics showed a significant additional PD diminution and CAL increase for modest and profound pockets ([@ref11]). Also in this investigation, the use of adjunctive MOX resulted in CAL increase and PD diminution with data comparable with previous studies that used AMOX+METRO in GAgP ([@ref1]; [@ref14]).

The current report did not observe any influence of age, gender, plaque and BOP at the patient level on CAL gain and PD reduction. Comparable inferences have been informed in multilevel studies ([@ref17]; [@ref5]; [@ref12]; [@ref18]). As was reported here, a relatively modest influence of patient\'s parameters in multilevel analysis has been generally documented ([@ref5]); [@ref5] suggest that patients with significant systemic conditions may cause more variability. In concordance with a previous multilevel studied where mechanical and surgical periodontal treatments were compared in aggressive and chronic periodontitis patients, more factors related with tooth level affecting therapy results than subject related features ([@ref12]).

Although in the present report smokers were excluded, multilevel studies revealed that smoking revealed a adverse influence on the magnitude of PD reduction ([@ref17]) and CAL gain ([@ref12]) in patients treated with nonsurgical ([@ref17]; [@ref12]) and surgical therapies ([@ref12]).

One weakness of this multilevel analysis is the six-month estimation phase. Categorically, a longer prospective observation of these patients will be indispensable to conclude if this adjunctive treatment would generate determined satisfactory modifications in the periodontal clinical parameters over time.

In conclusion, adjunctive MOX, non-molar and the interaction non-molar x MOX, interproximal sites and the interaction interproximal sites x MOX were factors in determining CAL increase and PD diminution in GAgP. The main cause of variability in CAL increase and PD diminution following adjunctive MOX was attributable to the tooth level. Finally, adjunctive MOX and their interactions showed higher clinical benefits at the tooth and site levels.

The Faculty of Dentistry of the Universidad de Antioquia, Medellín, Colombia, funded this investigation.
